Androgen receptor expression inversely correlates with immune cell infiltration in human epidermal growth factor receptor 2–positive breast cancer

2018 ◽  
Vol 103 ◽  
pp. 52-60 ◽  
Author(s):  
Johan M. van Rooijen ◽  
Si-Qi Qiu ◽  
Hetty Timmer-Bosscha ◽  
Bert van der Vegt ◽  
James E. Boers ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Androgen Receptor ◽  
Growth Factor ◽  
Immune Cell ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Immune Cell Infiltration ◽  
Epidermal Growth ◽  
Positive Breast Cancer

scholarly journals HER2-positive breast cancer and tyrosine kinase inhibitors: the time is now

2021 ◽  
Vol 7 (1) ◽  
Author(s):  
Ilana Schlam ◽  
Sandra M. Swain
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Tyrosine Kinase ◽  
Kinase Inhibitors ◽  
Growth Factor Receptor ◽  
Her2 Positive ◽  
Epidermal Growth ◽  
Positive Breast Cancer

AbstractHuman epidermal growth factor receptor 2 (HER2) positive breast cancer accounts for 20–25% of all breast cancers. Multiple HER2-targeted therapies have been developed over the last few years, including the tyrosine kinase inhibitors (TKI) lapatinib, neratinib, tucatinib, and pyrotinib. These drugs target HER2 and other receptors of the epidermal growth factor receptor family, therefore each has unique efficacy and adverse event profile. HER2-directed TKIs have been studied in the early stage and advanced settings and have shown promising responses. There is increasing interest in utilizing these drugs in combination with chemotherapy and /or other HER2-directed agents in patients with central nervous system involvement, TKIs have shown to be effective in this setting for which treatment options have been previously limited and the prognosis remains poor. The aim of this review is to summarize currently approved TKIs for HER2+ breast, key clinical trials, and their use in current clinical practice.

scholarly journals Epidermal growth factor receptor expression in breast cancer association with biologic phenotype and clinical outcomes

Cancer ◽  
2010 ◽  
Vol 116 (5) ◽  
pp. 1234-1242 ◽  
Author(s):  
Mothaffar F. Rimawi ◽  
Priya B. Shetty ◽  
Heidi L. Weiss ◽  
Rachel Schiff ◽  
C. Kent Osborne ◽  
...  
Keyword(s):  
Breast Cancer ◽  
Epidermal Growth Factor Receptor ◽  
Growth Factor ◽  
Epidermal Growth Factor ◽  
Clinical Outcomes ◽  
Growth Factor Receptor ◽  
Receptor Expression ◽  
Epidermal Growth
Sign in / Sign up

Export Citation Format

Share Document